Zobrazeno 1 - 10
of 26
pro vyhledávání: '"63"'
Autor:
Elke Verhey, C. Janneke van der Woude, Bettina E. Hansen, Hendrik M. van Dullemen, Ad A. van Bodegraven, Maurice G. Russel, Pieter Dewint, Bas Oldenburg, Marieke Pierik, Cyriel I J Ponsioen, Daniel W. Hommes
Publikováno v:
Gut, 63(2), 292-299. BMJ Publishing Group
Gut, 63(2), 292-299
Gut, 63(2), 292-299. BMJ PUBLISHING GROUP
Dewint, P, Hansen, B E, Verhey, E, Oldenburg, B, Hommes, D W, Pierik, M, Ponsioen, C I J, van Dullemen, H M, Russel, M, van Bodegraven, A A & van der Woude, C J 2014, ' Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI) ', Gut, vol. 63, no. 2, pp. 292-299 . https://doi.org/10.1136/gutjnl-2013-304488
Gut, 63(2), 292-299
Gut, 63(2), 292-299. BMJ PUBLISHING GROUP
Dewint, P, Hansen, B E, Verhey, E, Oldenburg, B, Hommes, D W, Pierik, M, Ponsioen, C I J, van Dullemen, H M, Russel, M, van Bodegraven, A A & van der Woude, C J 2014, ' Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI) ', Gut, vol. 63, no. 2, pp. 292-299 . https://doi.org/10.1136/gutjnl-2013-304488
Objective To assess whether a combination of adalimumab and ciprofloxacin is superior to adalimumab alone in the treatment of perianal fistulising Crohn's disease (CD).Design Randomised, double-blind, placebo controlled trial in eight Dutch hospitals
Autor:
Van Der Valk, Mirthe Emilie, Mangen, Marie Josée J, Leenders, Max, Dijkstra, Gerard, Van Bodegraven, Ad A., Fidder, Herma H., De Jong, Dirk J., Pierik, Marieke, Van Der Woude, C. Janneke, Romberg-Camps, Mariëlle J L, Clemens, Cees H M, Jansen, J.M., Mahmmod, Nofel, Van De Meeberg, Paul C., Van Der Meulen-De Jong, Andrea E., Ponsioen, Cyriel Y., Bolwerk, Clemens J M, Vermeijden, J. Reinoud, Siersema, Peter D., Van Oijen, Martijn G H, Oldenburg, Bas, LS IRAS EEPI GRA (Gezh.risico-analyse), IRAS RATIA-SIB, Risk Assessment of Toxic and Immunomodulatory Agents
Publikováno v:
van der Valk, M E, Mangen, M J J, Leenders, M, Dijkstra, G, van Bodegraven, A A, Fidder, H H, de Jong, D J, Pierik, M, van der Woude, C J, Romberg-Camps, M J L, Clemens, C H M, Jansen, J M, Mahmmod, N, van de Meeberg, P C, Jong, A, Ponsioen, C Y, Bolwerk, C J M, Vermeijden, J R, Siersema, P D, van Oijen, M G H & Oldenburg, B 2014, ' Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF alpha therapy: results from the COIN study ', Gut, vol. 63, no. 1, pp. 72-79 . https://doi.org/10.1136/gutjnl-2012-303376
Gut, 63(1), 72-79. BMJ PUBLISHING GROUP
Gut, 63(1), 72-79. BMJ Publishing Group
Gut, 63, 1, pp. 72-9
Gut, 63(1), 72-79
Gut, 63, 72-9
Gut, 63(1), 72. BMJ Publishing Group
Gut, 63(1), 72-79. BMJ PUBLISHING GROUP
Gut, 63(1), 72-79. BMJ Publishing Group
Gut, 63, 1, pp. 72-9
Gut, 63(1), 72-79
Gut, 63, 72-9
Gut, 63(1), 72. BMJ Publishing Group
Item does not contain fulltext OBJECTIVE: The introduction of anti tumour necrosis factor-alpha (anti-TNFalpha) therapy might impact healthcare expenditures, but there are limited data regarding the costs of inflammatory bowel diseases (IBD) followin
Autor:
Manichanh, Chaysavanh, Eck, Anat, Varela, Encarna, Roca, Joaquim, Clemente, José C, González, Antonio, Knights, Dan, Knight, Rob, Estrella, Sandra, Hernandez, Carlos, Guyonnet, Denis, Accarino, Ana María, Santos, Javier, Malagelada, Juan-R, Guarner, Francisco, Azpiroz Vidaur, Fernando, Universitat Autònoma de Barcelona
Publikováno v:
Gut
Digital.CSIC. Repositorio Institucional del CSIC
instname
Gut, vol 63, iss 3
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Manichanh, C; Eck, A; Varela, E; Roca, J; Clemente, JC; González, A; et al.(2014). Anal gas evacuation and colonic microbiota in patients with flatulence: Effect of diet. Gut, 63(3), 401-408. doi: 10.1136/gutjnl-2012-303013. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/807244bg
Digital.CSIC. Repositorio Institucional del CSIC
instname
Gut, vol 63, iss 3
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Manichanh, C; Eck, A; Varela, E; Roca, J; Clemente, JC; González, A; et al.(2014). Anal gas evacuation and colonic microbiota in patients with flatulence: Effect of diet. Gut, 63(3), 401-408. doi: 10.1136/gutjnl-2012-303013. UC San Diego: Retrieved from: http://www.escholarship.org/uc/item/807244bg
Chaysavanh Manichanh et al.
Objective: To characterise the influence of diet on abdominal symptoms, anal gas evacuation, intestinal gas distribution and colonic microbiota in patients complaining of flatulence. Design Patients complaining of fla
Objective: To characterise the influence of diet on abdominal symptoms, anal gas evacuation, intestinal gas distribution and colonic microbiota in patients complaining of flatulence. Design Patients complaining of fla
Publikováno v:
Gut. 39(4)
BACKGROUND: Various histological classifications developed for nodal lymphomas failed to be of value in extranodal lymphomas. More recently, gastric lymphoma is considered to represent a distinctive group derived from mucosa associated lymphoid tissu
Autor:
Severine Vermeire, Ana G. Vigo, Johannes Schumacher, Markus M. Nöthen, Mira M. Wouters, Elena Urcelay, Giovanni Zaninotto, Anna Latiano, Julio Perez de la Serna, Guy E. Boeckxstaens, Jessica Becker, Manuel Mattheisen, Luigi Laghi, Diether Lambrechts, Vito Annese, Michael Knapp, Rosario Cuomo, Hauke Lang, Wout O. Rohof, Uberto Fumagalli, Antonio Ruiz de León, Isabelle Cleynen, Giovanni Sarnelli, Michaela Mueller, Jan Tack, Ines Gockel, Orazio Palmieri
Publikováno v:
Wouters, M M, Lambrechts, D, Becker, J, Cleynen, I, Tack, J, Vigo, A G, Ruiz de León, A, Urcelay, E, Pérez de la Serna, J, Rohof, W, Annese, V, Latiano, A, Palmieri, O, Mattheisen, M, Mueller, M, Lang, H, Fumagalli, U, Laghi, L, Zaninotto, G, Cuomo, R, Sarnelli, G, Nöthen, M M, Vermeire, S, Knapp, K M, Gockel, I, Schumacher, J & Boeckxstaens, G E 2013, ' Genetic variation in the lymphotoxin-α (LTA)/tumour necrosis factor-α (TNFα) locus as a risk factor for idiopathic achalasia ', Gut . https://doi.org/10.1136/gutjnl-2013-304848
Gut, 63(9), 1401-1409. BMJ Publishing Group
Gut, 63(9), 1401-1409. BMJ Publishing Group
BACKGROUND: Idiopathic achalasia is a rare motor disorder of the oesophagus characterised by neuronal loss at the lower oesophageal sphincter. Achalasia is generally accepted as a multifactorial disorder with various genetic and environmental factors
Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study
Autor:
Caspar W. N. Looman, Ernst J. Kuipers, Gerrit A. Meijer, Mark van Blankenstein, M.K. Casparie, Pieter J F de Jonge
Publikováno v:
de Jonge, P J F, Blankenstein, N, Looman, C W N, Casparie, M K, Meijer, G A & Kuipers, E J 2010, ' Risk of malignant progression in patients with Barrett's oesophagus: a Dutch nationwide cohort study ', Gut, vol. 59, no. 8, pp. 1030-1036 . https://doi.org/10.1136/gut.2009.176701
Gut, 59(8), 1030-1036. BMJ Publishing Group
Gut, 59(8), 1030-1036. BMJ Publishing Group
Background Reported incidence rates of oesophageal adenocarcinoma (OAC) in Barrett's oesophagus (BO) vary widely. As the effectiveness of BO surveillance is crucially dependent on this rate, its clarification is essential. Methods To estimate the rat
Autor:
Parambir S. Dulai, Laurent Peyrin-Biroulet, Corey A. Siegel, Jean-Frederic Colombel, William J. Sandborn
Publikováno v:
Gut
Gut, BMJ Publishing Group, 2014, 63 (12), pp.1843-1853. ⟨10.1136/gutjnl-2014-307126⟩
Gut, BMJ Publishing Group, 2014, 63 (12), pp.1843-1853. ⟨10.1136/gutjnl-2014-307126⟩
The treatment of IBD has evolved significantly over the past 15 years. Historically, steroids and immunosuppressive drugs, such as methotrexate (MTX), azathioprine (AZA) and 6-mercaptopurine (6-MP) had been the mainstay of therapy. When infliximab (I
Publikováno v:
Gut. 43:29-32
Background—The appropriate medical treatment of patients with ulcerative colitis is determined largely by the severity of symptoms. Hospital assessment of the severity of disease activity includes investigation of laboratory indices and sigmoidosco
Autor:
Lars Kristian Munck, Ole Østergaard Thomsen, Bent Ascanius Jacobsen, Jan Fallingborg, Anne Sophie Oxholm, Lisbet Ambrosius Christensen, Jakob Kjellberg, Klaus Bendtzen, Mark A. Ainsworth, Gitte Pedersen, Casper Steenholdt, Jens Kjeldsen, Jørn Brynskov
Publikováno v:
Steenholdt, C, Brynskov, J, Thomsen, O Ø, Munck, L K, Fallingborg, J, Christensen, L A, Pedersen, G, Kjeldsen, J, Jacobsen, B A, Oxholm, A S, Kjellberg, J, Bendtzen, K & Ainsworth, M A 2014, ' Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment : a randomised, controlled trial ', Gut, vol. 63, no. 6, pp. 919-927 . https://doi.org/10.1136/gutjnl-2013-305279
OBJECTIVE: Although the reasons for secondary loss of response to infliximab (IFX) maintenance therapy in Crohn's disease vary, dose intensification is usually recommended. This study investigated the cost-effectiveness of interventions defined by an
Publikováno v:
Gut. 38:322-327
To evaluate the effects of a gluten free diet on bone mineral density in untreated adult patients with coeliac disease, 63 patients (17-79 years, 35 women) were examined at diagnosis and after one year taking a gluten free diet. Bone mineral density